<DOC>
	<DOCNO>NCT02217826</DOCNO>
	<brief_summary>In single-dose , randomize , 5-way cross-over study , healthy volunteer treat high approve dose octreotide , three different dos Somatoprim ( DG3173 ) placebo control . The main purpose study investigate effect treatment control plasma glucose well secretion insulin glucagon follow standard meal .</brief_summary>
	<brief_title>Single Dose Pharmacodynamic Pharmacokinetic Study DG3173</brief_title>
	<detailed_description />
	<mesh_term>Octreotide</mesh_term>
	<criteria>Ethnic origin : Caucasian Body Mass Index ( BMI ) : 1927 kg/m2 inclusive Medical history without clinically relevant pathology Physical examination parameter without sign clinically relevant pathology Electrocardiogram record without sign clinically relevant pathology , particular QTc ( Bazett ) &lt; 450 m Values hematology biochemistry test blood urine within normal range show clinically relevant deviation judge Investigator ( particular alanine transaminase , aspartate transaminase , lactate dehydrogenase , gamma glutamyl transferase , alkaline phosphatase , bilirubin , Î±amylase ) Subjects partner child bear potential must willing practice medically approve method contraception ( e.g. , condom combination hormonal contraception intrauterine device diaphragm spermicide first drug administration one month participation study vasectomize since &gt; 6 month partner sterilize since &gt; 6 month Having give write informed consent studyrelated activity carry Evidence clinically relevant pathology disease Any history moderate severe hypertension , hypotension orthostatic hypotension Mental handicap Legal incapacity Any history clinically important emotional and/or psychiatric illness clinically important neurological disorder and/or epilepsy Chronic diarrhea acute chronic gastrointestinal disorder Presence history endocrine disorder Presence history gallstone disease Known hypersensitivity study drug constituent study drug History relevant allergy , especially drug and/or food allergy Strict vegetarian Regular treatment medication three month prior randomization Receipt prescription nonprescription medication , include multi vitamin preparation within 14 day prior randomization duration study Use St. John 's Wort Ginkgo Biloba ( also know Ginkgo Bilbao ) within 48 hour prior randomization Participation clinical study within 30 day prior randomization Donation blood ( 450 ml ) within 60 day prior randomization Receipt blood , blood product plasma derivates one year prior randomization Regular smoking &gt; 5 cigarette per day within past three month Any history alcohol abuse drug addiction Known consumer drug abuse Known infect HBsAg , antiHCV , antiHIV1 HIV2 Consumption abnormal quantity coffee tea ( i.e. , 5 cup per day [ 1 cup = 150 ml ] ) Any disease Investigator 's opinion would exclude subject study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>